Issue |
Date |
Size |
Main Topics |
51 |
July 2020 |
268 KB |
- Update on Dolutegravir for children
- Isoniazid preventive therapy in pregnancy: update
|
50 |
October 2019 |
379 KB |
- The importance of the gut microbiota to health in HIV
- Update on risk for neural tube disorders for women on dolutegravir at conception: downgraded but real risk
- No clinically significant interaction between dolutegravir and valproate
|
49 |
March 2019 |
282 KB |
- Tuberculosis Preventive Therapy for Adults
- Undetectable = Untransmittable (U=U)
- Important drug-drug interactions with dolutegravir
|
48 |
July 2018 |
298 KB |
- Potential safety issue affecting HIV+ women taking dolutegravir at the time of conception
- New WHO guidelines for induction therapy in cryptococcal meningitis
- Treatment of cytomegalovirus (CMV) retinitis
- Isoniazid preventive therapy (IPT) in pregnancy
|
47 |
February 2018 |
377 KB |
- Dolutegravir in pregnancy
- Is there still a role for nevirapine?
- The Xpert MTB/RIF Ultra: increased sensitivity for diagnosing HIV-associated TB with a small increase in false positive results
- Treatment of multi-drug resistant gonorrhoea - what's in the pipeline?
|
46 |
September 2017 |
312 KB |
- Severe efavirenz-induced ataxia and encephalopathy
- Prolonged post-treatment virologic control in a South African HIV+ child after early antiretroviral therapy - implications for the future?
- The DAWNING trial: dolutegravir in second-line ART
|
45 |
March 2017 |
368 KB |
- Early ART initiation as a factor in combating antibiotic resistance
- Dolutegravir: not as monotherapy
- BREATHER - Can HIV+ youth safely have a weekend off their antiretroviral medication?
- Diagnosing "elite controllers"
|
44 |
October 2016 |
378 KB |
- Rifabutin dosing with protease inhibitors
- Drug-drug interactions involving second generation NNRTIs
- Pure Red Cell Aplasia in HIV
|
43 |
June 2016 |
411 KB |
- Dolutegravir: its use in adult patients
- Dolutegravir: its use in paediatric patients
- Drug-drug interactions between antiretrovirals and itraconazole
- Zika and HIV
|
42 |
February 2016 |
194 KB |
- Do elite controllers need ART?
- Early infant diagnosis of HIV - shifting paradigms
- Lifelong ART should be offered to ALL HIV-infected patients regardless of CD4 count
- Pneumococcal vaccination in HIV-infected persons
|
41 |
September 2015 |
444 KB |
- Probiotics and HIV
- Improved treatment outcomes in patients with XDR TB in South Africa
- HIV tests in children on ART
- Management of hyperlipidaemia in patients on protease inhibitors
- Cross-reactivity between darunavir and co-trimoxazole
- New 0199 tariff claiming process
|
40 |
July 2015 |
551 KB |
- Rilpivirine (RPV) in pregnancy
- Is there a need for 6-monthly CD4 monitoring in patients with stable virological suppression on ART?
- Twitter for the busy Clinician - Opening up a world of HIV-related information
- The role of micronutrient supplementation in adults
|
39 |
March 2015 |
524 KB |
- HIV-positive-to-HIV-positive renal transplantation
- Pre-exposure prophylaxis (PrEP): recent findings add to the evidence that it is effective as an HIV prevention tool
- Use of raltegravir in children
- Balancing risks and benefits in post exposure prophylaxis
|
38 |
November 2014 |
175 KB |
- Abacavir-based regimens in patients with high viral loads
- Proton pump inhibitor, H2 receptor blocker and antacid drug interactions with atazanavir/ritonavir
- Update on the Mississippi child - a reality check
- Maraviroc
- A festive reflection
|
37 |
August 2014 |
161 KB |
- The EARNEST trial: new evidence regarding efficacy of second line ART regimens
- New drug profile: rilpivirine
- The value of a psychological report in treatment failure
- Clinical Case Report - 35 year old male patient on a PMB Medical Scheme Option (Subject to State Protocols)
|
36 |
December 2013 |
118 KB |
- Key principles in the management of patients with suspected drug-induced liver injury (DILI) while on TB treatment (with or without ART)
- The perinatally infected adolescent
- Rifabutin in HIV medicine
- Should one discontinue co-trimoxazole prophylaxis in children established on ART?
|
35 |
August 2013 |
131 KB |
- Fixed dose combination antiretrovirals containing TDF, FTC/3TC and efavirenz
- Combination induction therapy for cryptococcal meningitis
- Isoniazid preventive therapy for people on ART
- An approach to weight loss in HIV-infected patients
- World Health Organization raises the bar
|
34 |
April 2013 |
165 KB |
- Etravirine
- Potential Cure of HIV in an infant - The Mississippi child -
What can we learn? Can we already change our practice?
- Use of Pre-Exposure Prophylaxis
- 20th Conference on Retroviruses and Opportunistic Infections
|
33 |
December 2012 |
217 KB |
- Practice Point - "Lipodystrophy" due to an unexpected drug interaction
- Timing of ART in patients with cryptococcal meningitis
- Abacavir or Tenofovir in 1st line ART?
- A Festive Reflection
|
32 |
June 2012 |
126 KB |
- National Department of Health Guidelines on the Management of Drug-resistant TB
- Study of switching to atazanavir for lipodystophy
- Reporting Adverse Drug Reactions
- Tenofovir for children and adolescents
|
31 |
February 2012 |
121 KB |
- The conundrum of infant feeding for HIV infected women continues
- Tenofovir and aminoglycosides
- What if my patient's CD4 count does not rise on ART
- Isoniazid preventive therapy
|
30 |
November 2011 |
126 KB |
- Managing fat gain in patients on antiretroviral therapy
- TB treatment in patients on second-line ART
- Lopinavir/ritonavir and Congenital Adrenal Hyperplasia in exposed infants?
- Developments in HIV renal transplantation
- Report back from the Mind, Body, HAART Symposium - Integrating mental health into HIV care
|
29 |
June 2011 |
111 KB |
- ART for Prevention
- Cryptococcal Antigen Screening in Patients with CD4 <= 100
|
28 |
May 2011 |
121 KB |
- Efavirenz Dose for Paediatric Patients
- Raltegravir: What is the Place of the New Kid on the Block?
- When is the Optimal Time to Start ART in Patients with TB? Recent findings
- African RCT of Influenza Vaccination in HIV Shows Benefit and Safety
|
27 |
December 2010 |
121 KB |
- Pre-exposure prophylaxis
- CD4 counts and percentages in children
- ART resistance, genotype resistance testing and archiving
- Amphotericin B
|
26 |
October 2010 |
121 KB |
- Patients with poor adherence to first line ART (2 NRTIs + 1 NNRTI) who have a persistently non-suppressed viral load
- Antimalarial chemoprophylaxis and treatment
- Newer protease inhibitors do not cause diabetes
|
25 |
July 2010 |
161 KB |
- Single drug switch from stavudine (or zidovudine) to tenofovir
- Long term isoniazid preventive therapy for HIV-infected adults: new evidence
- Immunization and HIV in adults
- Immunization in HIV-infected children and adolescents - emerging perspectives in 2010
|
24 |
February 2010 |
173 KB |
- HIV and pandemic influenza; lessons learnt and what to expect?
- Differential Diagnoses to consider in a patient with suspended TB
- Using nevirapine-based are in patients with TB
- Use of Ritonavir(Norvir®) as single protease infibitor in fants and childern
- Discontinuation Notice: Kaletra® soft gel capsules
|
23 |
October 2009 |
168 kb |
- When is the best time to start antiretroviral therapy?
- Elective caesarean sections and HIV transmission
- Genotyping testing for antiretroviral resistance
- Use of STAVUDINE(D4T) as part of combination therapy
- Antibiotics to prevent STIs POST SEXUAL ASSAULT
|
22 |
April 2009 |
167 kb |
- Antiretrovirals and the liver
- Isoniazid (INH) prophylaxis for HIV-infected children
- Isoniazid preventive therapy for HIV-infected healthcare workers
- Risk factors for nephrotoxicity in patients on tenofovir
- Zidovudine (AZT) dose adjustment for infants
- Pneumonia in patients with HIV infection
|
21 |
January 2009 |
429 kb |
- Abacavir and the risk of myocardial infarction
- New insights in infant feeding – breast versus formula
- New Southern African HIV Clinicians Society Guidelines for Postexposure Prophylaxis
- Switching antiretrovirals for lipodystrophy
|
20 |
June 2008 |
209 kb |
- Antiretroviral therapy and the risk of myocardial infarction
- Aluvia tablets replace Kaletra
- Diagnosis of Mycobacterium Avium Complex (MAC) infection
- TDF (Tenofovir Disporoxil Fumarate) in special situations
- Antiretroviral resistance testing (genotyping)
|
19 |
February 2008 |
212 kb |
- Aid for AIDS Clinical Newsletter – Issue 19
- Double-boosted protease inhibitor therapy for salvage ART: lack of evidence of benefit
- Diagnosing and treating smear negative and extrapulmonary Tuberculosis in HIV-infected patients
- Atazanavir in pregnancy
- Fluconazole and pregnancy
- Nutritional Management of the HIV positive patient “facts, fallacies and folk-lore”
- Monitoring patients on tenofovir – an update
- Completing the AfA application form
|
18 |
November 2007 |
html |
- Atazanavir
- Resistance mutations and atazanavir
- Early antiretroviral therapy (ART) in infants
- Hepatotoxicity when using adjusted dose Kaletra® with rifampicin
- Clinical, virological and immunological responses to HAART
- NNRTI vs boosted PI regimens
|
17 |
July 2007 |
146 KB |
- The use of Tenofovir Disoproxil Fumarate (TDF) in HAART regimens
- Resistance patterns associated with decreased tenofovir efficacy
- Emtricitabine (FTC)
- Tenofovir: Side effects and toxicities
- Hepatitis B
- The use of tenofovir in pregnancy and in paediatric patients
- Monitoring patients on tenofovir
- Viread® and Truvada®
- Tenofovir drug interactions
|
16 |
March 2007 |
110 KB |
- Contraception and antiretroviral therapy
- Monitoring lipids and glucose
- The SMART study
- Breast feeding in HIV-infected and exposed infants - paradigm shift
- Antiretroviral therapeutic drug monitoring
- Monitoring and promoting adherence to therapy with courier pharmacies
|
15 |
December 2006 |
14 KB |
- Dose of Stavudine
- Patients who Switch to Nevirapine with Higher CD4 Counts are not at Increased Risk of Hepatotoxicity
- Antiretroviral Resistance Testing
- Routine Testing for HIV Infection
- Post Exposure Prophylaxis (PEP) - Remember to Assess the Risks and Benefits
- Pneumococcal Vaccine for Children
|
14 |
June 2006 |
15 KB |
|
14 |
June 2006 |
115 KB |
- Breastfeeding in HIV-Infected Infants
- Triomune-40 Tablets are Available
- Referring Patients to Public Sector ARV Clinics
- Bacterial Pneumonia in HIV+ Adults
- Using Kaletra with Rifampicin
|
13 |
January 2006 |
126 KB |
- AfA awarded the HIV Disease Management contract for GEMS
- Discontinuing fluconazole prophylaxis following cryptococcal meningitis
- Tenofovir plus didanosine (DDI)
- Switching stavudine (D4T) to an alterative agent
|
12 |
October 2005 |
146 KB |
- Management of Patients with Myperlactataemia / Lactic Acidosis
- Doses in Renal Failure
- Enteric Coated Videx Capsules Available
- HAART Hypertension
|
11 |
June 2005 |
59 KB |
- New AfA guidelines for initiating HAART in adults
- Management of isolated elevated Gamma Glutamyl Transpeptidase (GGT) levels in HIV
- WHO Clinical Stage III and IV conditions
- Treating PCP in patients who are allergic to Cotrimoxazole
- AfA Clinical Guildelines - 5th Edition
|
10 |
February 2005 |
71 KB |
- Management of HIV - Associated Kaposi's Sarcoma (KS)
- Generic Antiretrovirals ARVs)
- Scheme changes for 2005
- FDA Public Health Advisory for Nevirapine
|
9 |
August 2004 |
62 KB |
- WHO clinical staging
- The role of Tenofovir DF (Viread)
- Protease inhibitor induced diarrhoea
- Benefit booking
- Making major decisions on CD4+ counts
- Tuberculosis and ART
- Generic antiretrovirals
|
8 |
April 2004 |
71 KB |
- Nevirapine and pregnancy - new concerns
- Immune "boosters" in HIV infection
- AfA and generic antiretroviral agents
- Increase in 0199 payment
- Scheme changes for 2004
- Kaletra and Rifampicin
- HAART and Porphyria
|
7 |
November 2003 |
59 KB |
- Voluntary Counselling and Testing
- Non-nucleoside reverse transcriptase inhibitor in the internal regimen
- AfA and generic antiretroviral agents
- Death knell for structured treatment interruptions
- The Medscheme Price List (MPL)
|
6 |
August 2003 |
78 KB |
- New AfA criteria for initiating ART
- Pharmaceutical Courier Services
- ICU management of HIV patients
- HIV rapid testing
|
5 |
March 2003 |
55 KB |
- The role of nelfinavir (Vira-cept)
- Changing from dual NRTI therapy to HAART
- Guidelines for managing Lipid disorders
- Structured treatment interruptions
|
4 |
December 2002 |
81 KB |
- New guidelines for initiating Antiretroviral Therapy (ART)
- Scheme changes for 2003
- Corrections to the 4th edition of the Clinical guidelines
|
3 |
September 2002 |
61 KB |
- CD4 counts for dummies
- Mother-to-Child prophylaxis
|
2 |
March 2002 |
60 KB |
- HIV VIral loads for dummies
- Peripheral neuropathy
- Dealing with Cotrimoxazole intolerance
|
1 |
August 2001 |
65 KB |
- Tuberculosis and antiretroviral therapy
- Testing for resistance to HIV drugs
- Intensifying antiretroviral therapy
|
